| Formulary Chapter 3: Respiratory system - Full Section
|
Notes:
When prescribing inhalers the drug, device (e.g. MDI, Easibreathe, Autohaler, Accuhaler), strength (micrograms per inhalation), number of puffs per dose and frequency MUST be specified |
| Useful Links |
 NICE TA10: Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma |
 Asthma action plan child: Asthma UK |
|
Asthma management plan: Asthma UK |
|
LSCMMG: Asthma Treatment Guideline for Adults |
|
LSCMMG: Asthma Treatment Guideline for Children |
|
LSCMMG: Chronic Obstructive Pulmonary Disease (COPD) Desktop Guideline |
|
MART asthma plan |
|
MHRA Drug Safety Update :Nebulised asthma rescue therapy in children: home use of nebulisers in paediatric asthma should be initiated and managed only by specialists |
|
MHRA: Pressurised metered dose inhalers (pMDI): risk of airway obstruction from aspiration of loose objects |
|
NICE NG115: Chronic obstructive pulmonary disease in over 16s: diagnosis and management |
|
NICE NG209: Tobacco: preventing uptake, promoting quitting and treating dependence |
|
NICE NG80:Asthma: diagnosis, monitoring and chronic asthma management |
|
NICE TA38: Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years) |
| Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
|
|
03.01 |
Bronchodilators
(1,0)
|
|
03.01.01 |
Adrenoceptor agonists
(0,0)
|
|
03.01.01.01 |
Selective Beta2 agonists
(1,0)
|
|
|
Short-acting beta2 agonists
(4,0)
|
|
|
Long-acting beta2 agonists
(2,0)
|
|
03.01.02 |
Antimuscarinic bronchodilators
(6,0)
|
|
03.01.03 |
Theophylline
(3,0)
|
|
03.01.04 |
Compound bronchodilator preparations
(5,0)
|
|
|
Peak flow meters
(2,0)
|
|
|
Drug delivery devices
(4,0)
|
|
|
Nebuliser Diluent
(1,0)
|
|
03.02 |
Corticosteroids
(16,0)
|
|
03.03 |
Cromoglicate, related therapy and leukotriene receptor antagonists
(0,0)
|
|
|
Related therapy
(0,0)
|
|
03.03.02 |
Leukotriene receptor antagonists
(1,0)
|
|
03.03.03 |
Phosphodiesterase type-4 inhibitors
(1,0)
|
|
03.04 |
Antihistamines, hyposensitisation, and allergic emergencies
(0,0)
|
|
03.04.01 |
Antihistamines
(0,0)
|
|
|
Non-sedating antihistamines
(5,0)
|
|
|
Sedating antihistamines
(3,0)
|
|
03.04.02 |
Allergen Immunotherapy
(8,0)
|
|
|
Omalizumab/ Tezepelumab
(3,0)
|
|
03.04.03 |
Allergic emergencies
(0,0)
|
|
|
Anaphylaxis
(1,0)
|
|
|
Angioedema
(4,0)
|
|
|
Intramuscular adrenaline (epinephrine)
(1,0)
|
|
|
Intravenous adrenaline (epinephrine)
(1,0)
|
|
|
Self-administration of adrenaline (epinephrine)
(0,0)
|
|
03.05 |
Respiratory stimulants and pulmonary surfactants
(0,0)
|
|
03.05.01 |
Respiratory stimulants
(2,0)
|
|
03.05.02 |
Pulmonary surfactants
(1,0)
|
|
03.06 |
Oxygen
(0,0)
|
|
|
Long-term oxygen therapy
(0,0)
|
|
|
Short burst oxygen therpary
(0,0)
|
|
|
Ambulatory oxygen therapy
(0,0)
|
|
|
Oxygen therapy equipment
(0,0)
|
|
|
Arrangements for supplying oxygen
(0,0)
|
|
03.07 |
Mucolytics
(9,0)
|
|
|
Dornase alfa
(1,0)
|
|
|
Hypertonic Sodium Chloride
(3,0)
|
|
03.09 |
Cough preparations
(0,0)
|
|
03.11 |
Antifibrotics
(2,0)
|
|
03.12 |
Other devices
(1,0)
|
